Lessons from the world’s largest hepatitis C elimination program: impact on primary liver cancer burden in Egypt: a global burden of disease analysis with 2050 projections

Introduction Primary liver cancer remains a leading cause of cancer-related mortality worldwide, with Egypt representing a uniquely high-burden setting due to historically widespread hepatitis C virus infection. This study aimed to comprehensively evaluate long-term trends in the burden of Primary liver cancer in Egypt from 1990 to 2023, with particular emphasize on the impact of the national HCV elimination campaign, and project future trends through 2050. Methods Data were obtained from the Global Burden of Disease 2023 database. Age-standardized incidence, mortality, and disability-adjusted life years (DALYs), together with prevalence rates, for Primary liver cancer were analyzed by sex and underlying etiology. Future projections to 2050 were generated using the GBD forecasting framework. Results Between 1990 and 2023, age-standardized incidence, mortality, and DALY rates for PLC in Egypt declined overall, with the steepest reductions observed between 2014 and 2019, coinciding with nationwide HCV eradication efforts. However, a rebound in incidence and mortality was observed after 2019. HCV remained the leading cause of Primary liver cancer mortality throughout the study period, although its contribution declined substantially. Notably, nonalcoholic steatohepatitis surpassed hepatitis B as the second leading cause of Primary liver cancer mortality by 2009. Projections suggest that comprehensive control of viral and metabolic risk factors could reduce Primary liver cancer mortality by nearly half by 2050. Conclusion Egypt’s HCV elimination campaign substantially reduced the burden of Primary liver cancer; however, long-term surveillance and integrated, multi-etiologic prevention strategies are essential to achieve durable reductions in Primary liver cancer burden.

Authors

Institutions

Publication Details

Journal
Egyptian Liver Journal
Published
2026-11-21
DOI
https://doi.org/10.1186/s43066-026-00563-y
Primary Topic
Hepatitis C virus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lessons from the world’s largest hepatitis C elimination program: impact on primary liver cancer burden in Egypt: a global burden of disease analysis with 2050 projections

Mohamed H. Eldesouki, Ahmed Abomhya, Eslam Elhossieny, S Elhanafi et al.
4 links
Egyptian Liver Journal
Hepatitis C virus research
article

Lessons from the world’s largest hepatitis C elimination program: impact on primary liver cancer burden in Egypt: a global burden of disease analysis with 2050 projections

Mohamed H. Eldesouki, Ahmed Abomhya, Eslam Elhossieny, S Elhanafi, Hazem Maarouf Abosheaishaa, Amr Raafat, Mohammed Y. Youssef, Mohamed Elgozair, Ehab Faheid, Mahmoud F. Hammad
article en

Abstract

Introduction Primary liver cancer remains a leading cause of cancer-related mortality worldwide, with Egypt representing a uniquely high-burden setting due to historically widespread hepatitis C virus infection. This study aimed to comprehensively evaluate long-term trends in the burden of Primary liver cancer in Egypt from 1990 to 2023, with particular emphasize on the impact of the national HCV elimination campaign, and project future trends through 2050. Methods Data were obtained from the Global Burden of Disease 2023 database. Age-standardized incidence, mortality, and disability-adjusted life years (DALYs), together with prevalence rates, for Primary liver cancer were analyzed by sex and underlying etiology. Future projections to 2050 were generated using the GBD forecasting framework. Results Between 1990 and 2023, age-standardized incidence, mortality, and DALY rates for PLC in Egypt declined overall, with the steepest reductions observed between 2014 and 2019, coinciding with nationwide HCV eradication efforts. However, a rebound in incidence and mortality was observed after 2019. HCV remained the leading cause of Primary liver cancer mortality throughout the study period, although its contribution declined substantially. Notably, nonalcoholic steatohepatitis surpassed hepatitis B as the second leading cause of Primary liver cancer mortality by 2009. Projections suggest that comprehensive control of viral and metabolic risk factors could reduce Primary liver cancer mortality by nearly half by 2050. Conclusion Egypt’s HCV elimination campaign substantially reduced the burden of Primary liver cancer; however, long-term surveillance and integrated, multi-etiologic prevention strategies are essential to achieve durable reductions in Primary liver cancer burden.

Egyptian Liver JournalVol. 16(1)
Brooklyn Hospital Center (US), Maimonides Medical Center (US), Mayo Clinic (US), The University of Texas MD Anderson Cancer Center (US), New York Medical College (US), Oklahoma City University (US), Danbury Hospital (US), Oklahoma Foundation for Digestive Research (US), Saint Michael's Medical Center (US), Nuvance Health (US), University of Oklahoma (US), Texas Tech University Health Sciences Center (US)
Good health and well-being
Hepatitis C virus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon